This Cu-binding capacity of metallothioneins is even exploited therapeutically in the treatment of Wilson’s disease [80]: oral application of high doses of Zn2+ causes the upregulation of metallothionein formation in enterocytes through the activation of metal regulatory transcription factor 1 (MTF1) [81]. The gene discussed is MTF1; the disease is Wilson disease.